Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Core Viewpoint - Eledon Pharmaceuticals is set to present updated clinical data on tegoprubart for kidney transplantation at the World Transplant Congress on August 6, 2025, with a conference call scheduled for the same day [1]. Group 1: Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3]. - The lead investigational product, tegoprubart, is an anti-CD40L antibody targeting the CD40 Ligand, which has significant therapeutic potential [3]. - The company is conducting studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [3]. Group 2: Clinical Study Details - The ongoing open-label Phase 1b study evaluates tegoprubart for preventing rejection in approximately 30 kidney transplant recipients [1]. - The updated clinical data will be presented at the World Transplant Congress in San Francisco, CA [1]. Group 3: Conference Call Information - A conference call and webcast will take place on August 6, 2025, at 4:30 p.m. ET to discuss the updated clinical data [1]. - Domestic callers can join by dialing 1-800-717-1738, while international callers can use 1-646-307-1865, with the conference ID being 34575 [2].